QUIDELORTHO CORP (QDEL)
Health Care · In-vitro diagnostics · NASDAQ
QuidelOrtho is a leading diagnostics company providing diverse testing solutions ranging from point-of-care molecular diagnostics to high-volume clinical laboratory immunoassay systems.
What QUIDELORTHO CORP does
QuidelOrtho is a global provider of innovative in-vitro diagnostic technologies and solutions. The company develops, manufactures, and markets a broad portfolio of diagnostic products, including molecular diagnostics, clinical chemistry and immunoassay testing, and point-of-care testing solutions.
Themes: clinical diagnostics, point-of-care testing, molecular diagnostics, transfusion medicine, immunoassay testing
Fundamentals
- Price$14.08 as of 2026-10-21 close
- Market cap$966M as of 2026-07-29 (share count; price 2026-10-21)
- 1-year return-52.8% 2025-10-21 close $29.83 → 2026-10-21 close $14.08
- P/En/a negative earnings
- Net margin-41.5% FY2025, SEC XBRL
- ROE-58.9% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity1.43 borrowings incl. finance leases / equity — 10-Q/10-K balance sheet 2026-06-28
- Revenue growth (YoY)-1.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+17.1% SEC XBRL
- Beta1.85 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How QDEL compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-28 | $631M | -$22M | -$93M | -$1.36 | -$111M† | $26M† |
| Q1 FY2026 2026-03-29 | $620M | -$32M | -$92M | -$1.35 | -$33M | $34M |
| Q4 FY2025 2025-12-28 | $724M† | -$66M† | -$131M† | -$1.90† | $132M† | $45M† |
| Q3 FY2025 2025-09-28 | $700M | -$705M | -$733M | -$10.78 | -$46M† | $49M† |
| Q2 FY2025 2025-06-29 | $614M | -$181M | -$255M | -$3.77 | -$47M† | $38M† |
| Q1 FY2025 2025-03-30 | $693M | $33M | -$13M | -$0.19 | $66M | $56M |
| Q4 FY2024 2024-12-29 | $708M† | -$100M† | -$178M† | -$2.62† | $64M† | $47M† |
| Q3 FY2024 2024-09-29 | $727M | $15M | -$20M | -$0.30 | $118M† | $47M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-28
- Cash and equivalents$123M
- Total debt$2.5B borrowings incl. finance leases (not tagged separately)
- Net debt$2.4B total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How QUIDELORTHO CORP looks technically
QUIDELORTHO CORP (QDEL) is trading 18.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 155 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago. It is 60.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 18.0% below its 200-day average, the long-term trend line — a long-term downtrend | -18.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.86 | $12.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.18 | $17.18 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 14.65. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 155 trading days ago — a "death cross", a bearish long-term signal | 155 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 28.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30) | 60.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($10.46 to $14.65) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.58 | $35.58 |
|---|---|---|
| From the 52-week high | it is 60.4% below its 52-week high (its highest price of the past year) | -60.4% |
| Above the 52-week low | it is 41.9% above its 52-week low (its lowest price of the past year) | +41.9% |
| Below the 52-week high | it is 60.4% below its highest point of the past year | 60.4% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $306.72 (set on 2020-08-06) | $306.72 |
| Given back of the 52-week move | over the past year its closes ranged ($9.96 to $35.38), and it has recovered roughly a quarter of its fall from last year’s high — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.67 to $26.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.2% |
| From the all-time high | it is 95.4% below its all-time high | -95.4% |
| Nearest price level | it is trading 3.3% below a resistance level at $14.55 — a price it turned at twice since 2026-03-27, most recently on 2026-10-14. Since 2024-10-21 it has 1 such level below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.3% |
| All-time low | its lowest closing price on record is $6.11 (set on 2005-07-11) | $6.11 |
| Above the all-time low | it is 130.4% above its all-time low | +130.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9489 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9489 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.63 and $15.04 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.63 – $12.33 – $15.04 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges below its 200-day average price (18.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.67× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 3.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -3.4% |
|---|---|---|
| Open gap | it gapped 2.8% above the previous close 13 sessions ago and has not traded back through the level it left behind at 10.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.8% |
| Gap filled | a 3.4% gap down opened on 2026-10-21 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 29.7 percentage points (the stock gained 29.7% while the market lost 0.1%) | +29.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 17.6 percentage points (the stock lost 14.3% while the market gained 3.3%) | -17.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.1 percentage points (the stock gained 16.9% while the market gained 9.8%) | +7.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 68.0 percentage points (the stock lost 52.8% while the market gained 15.2%) | -68.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 14.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $15.77 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -10.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $12.90 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +9.1% |
Price levels it has turned at before
QDEL last closed at $14.08 on 2026-10-21. Since 2024-10-21 it has turned at 1 price below its last close and 12 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.55 | Resistance | 3.3% above the last close | turned there twice · 2026-03-27 to 2026-10-14 |
| $15.52 | Resistance | 10.2% above the last close | turned there twice · 2026-07-08 to 2026-07-21 |
| $18.02 | Resistance | 27.9% above the last close | turned there twice · 2026-04-15 to 2026-08-03 |
| $9.93 | Support | 29.5% below the last close | turned there twice · 2026-05-11 to 2026-10-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $14.65.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $9.01 and $12.50 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-10-21.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.67 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$14.67 range $12.00 – $20.00; median $12.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for QDEL
- Consensus EPS estimate$0.1784 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.00113 (-0.6%) from $0.1795, on 2026-09-13, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant accumulated deficit and recent net losses","High leverage and significant interest expenses from borrowings","Integration and restructuring risks related to historical mergers and operations"]
What changed in the latest 10-Q
AI-assisted comparison of QDEL's 10-Q filed 2026-05-06 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) adds reference to 'inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions (such as the integration of LEX Diagnostics), strategic restructurings (such as the Optimization Plan), divestitures, spin-offs or discontinuances of certain business operations (such as the SAVANNA Exit)' in forward-looking statements section
- Newer filing adds 'changes in reimbursement rates for our products, including reimbursement rate reductions proposed by the China National Health Security Administration' as a risk factor
- Newer filing adds 'disruptions and challenges related to the ongoing conflicts in the Middle East' as a risk factor
- Newer filing adds reference to 'tariff-related developments' in addition to tariffs and trade policies
- Newer filing states the company has manufacturing facilities in 'the U.S., U.K. and China' versus older filing stating 'the U.S. and U.K.'
- Newer filing states customers are supported across 'more than 140 countries and territories' versus older filing's 'more than 130 countries and territories'
- Newer filing reports non-core revenue of '$24.7 million and $33.4 million for the three months ended March 29, 2026 and March 30, 2025, respectively'
- Newer filing reports three-month period ended March 29, 2026 with Total revenues of '$619.8 million' and respiratory products at '11%' of Total revenues
- Newer filing states reportable segments as 'North America, EMEA, China, JPAC and Latin America' versus older filing's structure
- Newer filing states U.S. donor screening portfolio wind-down 'is expected to be substantially complete by mid-year 2026'
- Removed:
- Older filing (2025-11-06) reference to 'integration' goals removed from forward-looking statements in newer filing
- Older filing references 'the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the Combinations or other acquisitions' removed from newer filing
- Older filing reference to 'failure to exercise the option to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline' removed from newer filing
- Older filing specific COVID-19 revenue figures and nine-month period data removed (not applicable to newer filing's three-month period)
- Older filing's statement that 'Latin America and JPAC are immaterial operating segments...included in "Other"' removed; newer filing lists these as reportable segments
- Older filing title 'Planned Wind-Down of U.S. Donor Screening Portfolio' changed to 'Wind-Down of U.S. Donor Screening Portfolio' in newer filing
- Older filing language 'we plan to wind-down' changed to 'we are winding-down' in newer filing
- Reworded:
- Forward-looking statements section: older filing mentions 'commercial, integration and other strategic goals' while newer filing states 'commercial and other strategic goals' (removed 'integration')
- Risk factors: older filing states 'inability to realize the anticipated benefits of acquisitions, debt refinancings, discontinuances of certain business operations' while newer filing consolidates language into 'inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions'
- Manufacturing facilities: older filing lists 'U.S. and U.K.' while newer filing adds 'China' to the list
- Geographic reach: updated from '130' to '140' countries and territories
- Business segment structure: older filing describes Latin America and JPAC as 'immaterial operating segments...included in "Other"' while newer filing lists them as reportable segments
- U.S. donor screening portfolio description: older filing uses 'plan to wind-down' while newer filing uses 'are winding-down', indicating progressed status
- Wind-down title changed from 'Planned' to active language in newer filing
- Notes:
- The older filing covers a nine-month period ended September 28, 2025, while the newer filing covers a three-month period ended March 29, 2026; period mismatch limits direct financial comparisons
- Newer filing text appears truncated at 'Restructuring and Other Charges' section; full comparison of that section not possible
- Some differences reflect temporal progression (e.g., wind-down status changes) rather than substantive restatements of historical facts
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for QDEL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding QDEL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 21,727,258
- Reported value $380,552,920
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about QDEL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
QDEL had 14,953,442 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
QDEL had 21.8% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.98 days to cover at the same settlement.
- Reported short interest (shares) 14,953,442
- Short interest (% of shares outstanding) 21.8%
- Prior settlement (shares) 14,190,525
- Reported change 5.38%
- Days to cover (reported) 10.98
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche Diagnostics (RHHBY)
- Abbott Laboratories (ABT)
- Siemens Healthineers (SMMNY)
- Danaher Corporation (DHR)
- Thermo Fisher Scientific (TMO)
- bioMérieux (BIM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare QDEL vs…
QUIDELORTHO CORP is found in…
QDEL ranks in…
Frequently asked questions
What does QUIDELORTHO CORP (QDEL) do?
QuidelOrtho is a global provider of innovative in-vitro diagnostic technologies and solutions. The company develops, manufactures, and markets a broad portfolio of diagnostic products, including molecular diagnostics, clinical chemistry and immunoassay testing, and point-of-care testing solutions.
What sector is QUIDELORTHO CORP (QDEL) in?
QUIDELORTHO CORP (QDEL) is classified in the Health Care sector. Its industry is In-vitro diagnostics. It trades on NASDAQ.
Who are QUIDELORTHO CORP's (QDEL) competitors?
Notable peers of QUIDELORTHO CORP (QDEL) include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation and Thermo Fisher Scientific. This peer set is informational only — not financial advice.
Is QUIDELORTHO CORP (QDEL) overbought or oversold right now?
QUIDELORTHO CORP (QDEL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 61, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on QDEL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.